# US 9,187,735 B2 · Metal abstraction peptide with superoxide dismutase activity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,187,735 B2 - Document ID: US9187735B2 - Status: Granted - Kind: B2 - Application number: 13/905,457 - Filed: 2013-05-30 - Published: 2013-12-12 - Granted: 2015-11-17 - Earliest claimed: 2012-06-01 - Assignees: University of Kansas; Echogen, Inc. - Applicants: University of Kansas; Echogen, Inc. - Inventors: Jennifer Ann Stowell Laurence; Mary Elizabeth Krause; Timothy A. Jackson; Amanda Michelle Glass; George Laurence - Web page: https://patentgrep.com/patent/US9187735B2 ## CPC - C12N 9/0089: {acting on superoxide as acceptor (1.15)} - C07K 14/62: Insulins - C12P 7/62: Carboxylic acid esters - C12Y 115/01001: Superoxide dismutase (1.15.1.1) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)} - C12Y: ENZYMES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Compositions comprising peptides that are capable of binding a metal are disclosed. Such compositions can be used for binding metal in a variety of contexts and environments. In various embodiments, peptides are used for antioxidant activity, anti-inflammatory activity, anti-pain therapy, as chemical reagents, and/or as superoxide dismutase mimics. ## Claims ### Claim 1 A method of treating a defect in superoxide dismutase in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of: i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually a sulfur-containing amino acid, wherein the peptide comprises at least 20 amino acids; and ii) a metal bound to the peptide. ### Claim 2 (depends on 1) The method of claim 1, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient. ### Claim 3 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is of all L-amino acids. ### Claim 4 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids. ### Claim 5 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids. ### Claim 6 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 7 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is included in a sequence XC1C2—Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 8 (depends on 1) The method of claim 1, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2—Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 9 (depends on 1) The method of claim 1, wherein the peptide comprises a basic amino acid adjacent to either X or C2. ### Claim 10 (depends on 1) The method of claim 1, wherein C1 and C2 are each cysteine. ### Claim 11 (depends on 10) The method of claim 10, wherein X is asparagine. ### Claim 12 (depends on 1) The method of claim 1, wherein the metal is a group 10 metal. ### Claim 13 (depends on 1) The method of claim 1, wherein the metal is nickel. ### Claim 14 (depends on 1) The method of claim 1, wherein the peptide and the metal are administered to the subject in a composition having a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1. ### Claim 15 (depends on 14) The method of claim 14, wherein the ratio is about 1:about 1. ### Claim 16 (depends on 1) The method of claim 1, wherein the sequence XC1C2 binds the metal. ### Claim 17 (depends on 1) The method of claim 1, wherein the metal is platinum. ### Claim 18 (depends on 1) The method of claim 1, wherein the metal is copper. ### Claim 19 (depends on 11) The method of claim 11, wherein the metal is platinum. ### Claim 20 (depends on 11) The method of claim 11, wherein the metal is copper. ### Claim 21 (depends on 1) The method of claim 1, wherein the peptide comprises no more than 500 amino acids. ### Claim 22 (depends on 1) The method of claim 1, wherein the amount is from about 1 mg to about 50 mg. ### Claim 23 (depends on 1) The method of claim 1, wherein a complex of the peptide and the metal acts as a preservative. ### Claim 24 (depends on 1) The method of claim 1, wherein a complex of the peptide and the metal acts as an antioxidant. ### Claim 25 (depends on 1) The method of claim 1, wherein the amount is from about 0.001% w/v to about 0.1% w/v. ### Claim 26 (depends on 1) The method of claim 1, wherein the administration is intravenous. ### Claim 27 A method of reducing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of: i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually a sulfur-containing amino acid, wherein the peptide comprises at least 20 amino acids; and ii) a metal bound to the peptide. ### Claim 28 (depends on 27) The method of claim 27, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient. ### Claim 29 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is of all L-amino acids. ### Claim 30 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids. ### Claim 31 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids. ### Claim 32 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 33 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is included in a sequence XC1C2—Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 34 (depends on 27) The method of claim 27, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2—Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 35 (depends on 27) The method of claim 27, wherein the peptide comprises a basic amino acid adjacent to either X or C2. ### Claim 36 (depends on 27) The method of claim 27, wherein C1 and C2 are each cysteine. ### Claim 37 (depends on 36) The method of claim 36, wherein X is asparagine. ### Claim 38 (depends on 27) The method of claim 27, wherein the metal is a group 10 metal. ### Claim 39 (depends on 27) The method of claim 27, wherein the metal is nickel. ### Claim 40 (depends on 27) The method of claim 27, wherein the peptide and the metal are administered to the subject in a composition having a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1. ### Claim 41 (depends on 40) The method of claim 40, wherein the ratio is about 1:about 1. ### Claim 42 (depends on 27) The method of claim 27, wherein the sequence XC1C2 binds the metal. ### Claim 43 (depends on 27) The method of claim 27, wherein the peptide comprises no more than 500 amino acids. ### Claim 44 (depends on 27) The method of claim 27, wherein the amount is from about 1 mg to about 5000 mg. ### Claim 45 (depends on 27) The method of claim 27, wherein a complex of the peptide and the metal acts as a preservative. ### Claim 46 (depends on 27) The method of claim 27, wherein a complex of the peptide and the metal acts as an antioxidant. ### Claim 47 (depends on 27) The method of claim 27, wherein the amount is from about 0.001% w/v to about 0.1% w/v. ### Claim 48 (depends on 27) The method of claim 27, wherein the administration is intravenous. ### Claim 49 (depends on 27) The method of claim 27, wherein the metal is platinum. ### Claim 50 (depends on 27) The method of claim 27, wherein the metal is copper. ### Claim 51 (depends on 37) The method of claim 37, wherein the metal is platinum. ### Claim 52 (depends on 37) The method of claim 37, wherein the metal is copper. ### Claim 53 A method of reducing inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of: i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually a sulfur-containing amino acid, wherein the peptide comprises at least 20 amino acids; and ii) a metal bound to the peptide. ### Claim 54 (depends on 53) The method of claim 53, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient. ### Claim 55 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is of all L-amino acids. ### Claim 56 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids. ### Claim 57 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids. ### Claim 58 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 59 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is included in a sequence XC1C2—Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 60 (depends on 53) The method of claim 53, wherein the sequence XC1C2 is included in a sequence Z1—XC1C2—Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids. ### Claim 61 (depends on 53) The method of claim 53, wherein the peptide comprises a basic amino acid adjacent to either X or C2. ### Claim 62 (depends on 53) The method of claim 53, wherein C1 and C2 are each cysteine. ### Claim 63 (depends on 62) The method of claim 62, wherein X is asparagine. ### Claim 64 (depends on 53) The method of claim 53, wherein the metal is a group 10 metal. ### Claim 65 (depends on 53) The method of claim 53, wherein the metal is nickel. ### Claim 66 (depends on 53) The method of claim 53, wherein the peptide and the metal are administered to the subject in a composition having a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1. ### Claim 67 (depends on 66) The method of claim 66, wherein the ratio is about 1:about 1. ### Claim 68 (depends on 53) The method of claim 53, wherein the sequence XC1C2 binds the metal. ### Claim 69 (depends on 53) The method of claim 53, wherein the peptide comprises no more than 500 amino acids. ### Claim 70 (depends on 53) The method of claim 53, wherein the amount is from about 1 mg to about 5000 mg. ### Claim 71 (depends on 53) The method of claim 53, wherein a complex of the peptide and the metal acts as a preservative. ### Claim 72 (depends on 53) The method of claim 53, wherein a complex of the peptide and the metal acts as an antioxidant. ### Claim 73 (depends on 53) The method of claim 53, wherein the amount is from about 0.001% w/v to about 0.1% w/v. ### Claim 74 (depends on 53) The method of claim 53, wherein the administration is intravenous. ### Claim 75 (depends on 53) The method of claim 53, wherein the metal is platinum. ### Claim 76 (depends on 53) The method of claim 53, wherein the metal is copper. ### Claim 77 (depends on 63) The method of claim 63, wherein the metal is platinum. ### Claim 78 (depends on 63) The method of claim 63, wherein the metal is copper.